Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05843643




Registration number
NCT05843643
Ethics application status
Date submitted
25/04/2023
Date registered
6/05/2023
Date last updated
26/11/2024

Titles & IDs
Public title
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Scientific title
SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE
Secondary ID [1] 0 0
2023-503655-10-00
Secondary ID [2] 0 0
M23-699
Universal Trial Number (UTN)
Trial acronym
SELECT-SLE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Upadacitinib
Treatment: Drugs - Placebo

Experimental: Study 1- Upadacitinib Dose A - Participants will receive upadacitinib dose A once daily for 52 weeks.

Placebo comparator: Study 1- Placebo - Participants will receive upadacitinib matching placebo once daily for 52 weeks.

Experimental: Study 2- Upadacitinib Dose A - Participants will receive upadacitinib dose A once daily for 52 weeks.

Placebo comparator: Study 2- Placebo - Participants will receive upadacitinib matching placebo once daily for 52 weeks.

Experimental: Study 3- Low Disease Activity Upadacitinib (LDA) Dose A - Participants in the upadacitinib arms from Study 1 or Study 2 with LDA will receive upadacitinib dose A once daily for 52 weeks.

Experimental: Study 3- Low Disease Activity Upadacitinib Dose B - Participants in the upadacitinib arms from Study 1 or Study 2 with LDA will receive upadacitinib dose B once daily for 52 weeks.

Experimental: Study 3- No LDA Upadacitinib Dose A - Participants in the upadacitinib arms from Study 1 or Study 2 with no LDA will receive upadacitinib dose A once daily for 52 weeks.

Experimental: Study 3- Upadacitininb Dose A - Participants in the placebo arms of Study 1 or Study 2 will receive upadacitinib Dose A once daily for 52 weeks.

Experimental: Study 3- Open Label Upadacitinib Dose A - Participants who experience a suspected systemic lupus erythematosus (SLE) flare may receive open label upadacitinib Dose A once daily for the remainder of the study.

Experimental: Study 3- Open Label Upadacitinib Dose B - Participants who reach \>= 65 years of age and are still on study drug may receive open-label upadacitinib Dose B once daily, and participants who experience a suspected SLE flare while on upadacitinib Dose B may receive upadacitinib Dose A for the remainder of the study.


Treatment: Drugs: Upadacitinib
Oral Tablets

Treatment: Drugs: Placebo
Oral Tablet
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving British Isles Lupus Assessment Group Based Combined Lupus Assessment (BICLA) Response
Timepoint [1] 0 0
At Week 52
Secondary outcome [1] 0 0
Percentage of Flares Participants Experiencing Over Time (Number of Flares Per Patient-Year)
Timepoint [1] 0 0
Week 52
Secondary outcome [2] 0 0
Percentage of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI) -4
Timepoint [2] 0 0
At Week 52
Secondary outcome [3] 0 0
Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS)
Timepoint [3] 0 0
At Week 52
Secondary outcome [4] 0 0
Time to First Flare per SELENA SLEDAI Flare Index (SFI)
Timepoint [4] 0 0
Week 52
Secondary outcome [5] 0 0
Percentage of Participants Achieving Oral Glucocorticoid Dose <=7.5 mg/day Prednisone-Equivalent
Timepoint [5] 0 0
From Week 44 to Week 52
Secondary outcome [6] 0 0
Percentage of Participants Achieving >= 50% Improvement in Tender or Swollen Joints
Timepoint [6] 0 0
Week 52
Secondary outcome [7] 0 0
Percentage of Participants Achieving >= 50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score
Timepoint [7] 0 0
Week 52
Secondary outcome [8] 0 0
Change from Baseline in Lupus Pain Numerical Rating Scale (NRS)
Timepoint [8] 0 0
Baseline to Week 52
Secondary outcome [9] 0 0
Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Version 4
Timepoint [9] 0 0
Baseline to Week 52
Secondary outcome [10] 0 0
Change from Baseline in 36-Item Short Form Health Survey (SF-36) Acute Physical Component Summary (PCS)
Timepoint [10] 0 0
Baseline to Week 52

Eligibility
Key inclusion criteria
* Clinical diagnosis of systemic lupus erythematosus (SLE) at least 24 weeks prior to screening as defined by the 2019 European Alliance of Associations for Rheumatology (EULAR)/ American College of Rheumatology (ACR) classification criteria for SLE.
* At Screening, must have at least one of the following:

* antinuclear antibody (ANA) positive (titer >= 1:80)
* anti-double stranded deoxyribonucleic acid (dsDNA) positive
* anti-Smith positive
* Hybrid systemic lupus erythematosus disease activity index (hSLEDAI) >= 6, of which >= 4 points are clinical (not based on laboratory criteria), independently reviewed by the MCDR at Screening. Clinical hSLEDAI score (not based on laboratory criteria) must be re-confirmed as >= 4 at the Baseline visit. Lupus headache or organic brain syndrome do not count towards the hSLEDAI points required for eligibility but should be documented on the hSLEDAI if present.
* Physician's Global Assessment (PhGA) >= 1 during screening period.
* On stable background treatment for >= 60 days prior to Baseline (with the exception of oral corticosteroid [OCS], which must be at a stable dose for >=14 days prior to Baseline) with

* antimalarial(s) [hydroxychloroquine <= 400 mg daily, chloroquine <= 500 mg daily, quinacrine <= 100 mg daily];
* and/or prednisone (or prednisone-equivalent) (<= 20 mg daily);
* and/or no more than 1 of the following: azathioprine (<= 150 mg daily), 6-mercaptopurine (<= 150 mg daily), mycophenolate mofetil (<= 2 g daily), mycophenolate sodium <= 1,440 mg/day, leflunomide (<= 20 mg daily), cyclosporine, tacrolimus, voclosporin (<= 23.7 mg twice daily), methotrexate (<= 25 mg weekly), or mizoribine (<= 150 mg daily).
Minimum age
18 Years
Maximum age
63 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Class III/IV lupus nephritis that was treated with induction therapy within the 6 months prior to Screening.
* Active neuropsychiatric SLE (excluding lupus headache) within the 6 months prior to Screening.
* SLE overlap syndromes including, but not limited to, rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, or mixed connective tissue disease (Sjögren's syndrome is permitted).
* Antiphospholipid syndrome and prior unprovoked venous or arterial thrombosis who are not on stable and adequate anticoagulation.
* Two or more episodes of herpes zoster, or one or more episodes of disseminated herpes zoster or herpes zoster ophthalmicus.
* History of malignancy, except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix.
* Pregnancy, breastfeeding, or considering becoming pregnant during the study.
* Clinically relevant or significant ECG abnormalities at Screening.
* Planned elective surgery that would impact study procedures or assessments through the completion of the Week 52 assessments.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/07/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/10/2027
Actual
Sample size
Target
1000
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,NT,SA,VIC,WA
Recruitment hospital [1] 0 0
Emeritus Research Sydney /ID# 256249 - Botany
Recruitment hospital [2] 0 0
Concord Repatriation General Hospital /ID# 257945 - Concord
Recruitment hospital [3] 0 0
Momentum Clinical Research /ID# 253542 - Darlinghurst
Recruitment hospital [4] 0 0
Royal Darwin Hospital /ID# 263160 - Tiwi
Recruitment hospital [5] 0 0
The Queen Elizabeth Hospital /ID# 253826 - Woodville
Recruitment hospital [6] 0 0
Emeritus Research /ID# 256800 - Camberwell
Recruitment hospital [7] 0 0
Monash Medical Centre /ID# 255678 - Clayton
Recruitment hospital [8] 0 0
Colin Bayliss Research and Teaching Unit /ID# 261077 - Victoria Park
Recruitment postcode(s) [1] 0 0
2019 - Botany
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [4] 0 0
0811 - Tiwi
Recruitment postcode(s) [5] 0 0
5011 - Woodville
Recruitment postcode(s) [6] 0 0
3124 - Camberwell
Recruitment postcode(s) [7] 0 0
3168 - Clayton
Recruitment postcode(s) [8] 0 0
6100 - Victoria Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Montana
Country [15] 0 0
United States of America
State/province [15] 0 0
New Hampshire
Country [16] 0 0
United States of America
State/province [16] 0 0
New Mexico
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
Belgium
State/province [24] 0 0
Antwerpen
Country [25] 0 0
Belgium
State/province [25] 0 0
Bruxelles-Capitale
Country [26] 0 0
Bosnia and Herzegovina
State/province [26] 0 0
Republika Srpska
Country [27] 0 0
Bosnia and Herzegovina
State/province [27] 0 0
Sarajevo
Country [28] 0 0
Brazil
State/province [28] 0 0
Bahia
Country [29] 0 0
Brazil
State/province [29] 0 0
Espirito Santo
Country [30] 0 0
Brazil
State/province [30] 0 0
Minas Gerais
Country [31] 0 0
Brazil
State/province [31] 0 0
Parana
Country [32] 0 0
Brazil
State/province [32] 0 0
Rio Grande Do Sul
Country [33] 0 0
Brazil
State/province [33] 0 0
Sao Paulo
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Sofia
Country [35] 0 0
Bulgaria
State/province [35] 0 0
Plovdiv
Country [36] 0 0
Bulgaria
State/province [36] 0 0
Ruse
Country [37] 0 0
Bulgaria
State/province [37] 0 0
Sofiya
Country [38] 0 0
Canada
State/province [38] 0 0
Alberta
Country [39] 0 0
Canada
State/province [39] 0 0
Manitoba
Country [40] 0 0
Chile
State/province [40] 0 0
Araucania
Country [41] 0 0
Chile
State/province [41] 0 0
Bio-Bio
Country [42] 0 0
Chile
State/province [42] 0 0
Region Metropolitana De Santiago
Country [43] 0 0
Chile
State/province [43] 0 0
Region Metropolitana Santiago
Country [44] 0 0
Chile
State/province [44] 0 0
Providencia
Country [45] 0 0
China
State/province [45] 0 0
Anhui
Country [46] 0 0
China
State/province [46] 0 0
Beijing
Country [47] 0 0
China
State/province [47] 0 0
Fujian
Country [48] 0 0
China
State/province [48] 0 0
Guangdong
Country [49] 0 0
China
State/province [49] 0 0
Hubei
Country [50] 0 0
China
State/province [50] 0 0
Hunan
Country [51] 0 0
China
State/province [51] 0 0
Inner Mongolia
Country [52] 0 0
China
State/province [52] 0 0
Jiangsu
Country [53] 0 0
China
State/province [53] 0 0
Jiangxi
Country [54] 0 0
China
State/province [54] 0 0
Jilin
Country [55] 0 0
China
State/province [55] 0 0
Shaanxi
Country [56] 0 0
China
State/province [56] 0 0
Shandong
Country [57] 0 0
China
State/province [57] 0 0
Shanghai
Country [58] 0 0
China
State/province [58] 0 0
Sichuan
Country [59] 0 0
China
State/province [59] 0 0
Tianjin
Country [60] 0 0
China
State/province [60] 0 0
Yunnan
Country [61] 0 0
China
State/province [61] 0 0
Zhejiang
Country [62] 0 0
Colombia
State/province [62] 0 0
Antioquia
Country [63] 0 0
Colombia
State/province [63] 0 0
Cundinamarca
Country [64] 0 0
Colombia
State/province [64] 0 0
Santander
Country [65] 0 0
Colombia
State/province [65] 0 0
Barranquilla
Country [66] 0 0
Croatia
State/province [66] 0 0
Grad Zagreb
Country [67] 0 0
Croatia
State/province [67] 0 0
Osjecko-baranjska Zupanija
Country [68] 0 0
Croatia
State/province [68] 0 0
Primorsko-goranska Zupanija
Country [69] 0 0
Croatia
State/province [69] 0 0
Splitsko-dalmatinska Zupanija
Country [70] 0 0
Estonia
State/province [70] 0 0
Harjumaa
Country [71] 0 0
Estonia
State/province [71] 0 0
Tartumaa
Country [72] 0 0
France
State/province [72] 0 0
Haute-Garonne
Country [73] 0 0
France
State/province [73] 0 0
Ile-de-France
Country [74] 0 0
France
State/province [74] 0 0
Rhone
Country [75] 0 0
Germany
State/province [75] 0 0
Nordrhein-Westfalen
Country [76] 0 0
Germany
State/province [76] 0 0
Rheinland-Pfalz
Country [77] 0 0
Germany
State/province [77] 0 0
Berlin-buch
Country [78] 0 0
Germany
State/province [78] 0 0
Frankfurt am Main
Country [79] 0 0
Greece
State/province [79] 0 0
Attiki
Country [80] 0 0
Greece
State/province [80] 0 0
Kriti
Country [81] 0 0
Guatemala
State/province [81] 0 0
Guatemala
Country [82] 0 0
Hungary
State/province [82] 0 0
Baranya
Country [83] 0 0
Hungary
State/province [83] 0 0
Hajdu-Bihar
Country [84] 0 0
Hungary
State/province [84] 0 0
Veszprem
Country [85] 0 0
Hungary
State/province [85] 0 0
Gyula
Country [86] 0 0
Israel
State/province [86] 0 0
H_efa
Country [87] 0 0
Israel
State/province [87] 0 0
HaMerkaz
Country [88] 0 0
Israel
State/province [88] 0 0
HaTsafon
Country [89] 0 0
Israel
State/province [89] 0 0
Tel-Aviv
Country [90] 0 0
Israel
State/province [90] 0 0
Yerushalayim
Country [91] 0 0
Italy
State/province [91] 0 0
Roma
Country [92] 0 0
Italy
State/province [92] 0 0
Ancona
Country [93] 0 0
Italy
State/province [93] 0 0
Pisa
Country [94] 0 0
Japan
State/province [94] 0 0
Chiba
Country [95] 0 0
Japan
State/province [95] 0 0
Fukuoka
Country [96] 0 0
Japan
State/province [96] 0 0
Hokkaido
Country [97] 0 0
Japan
State/province [97] 0 0
Miyagi
Country [98] 0 0
Japan
State/province [98] 0 0
Miyazaki
Country [99] 0 0
Japan
State/province [99] 0 0
Okayama
Country [100] 0 0
Japan
State/province [100] 0 0
Okinawa
Country [101] 0 0
Japan
State/province [101] 0 0
Saitama
Country [102] 0 0
Japan
State/province [102] 0 0
Tokyo
Country [103] 0 0
Japan
State/province [103] 0 0
Yamanashi
Country [104] 0 0
Korea, Republic of
State/province [104] 0 0
Chungcheongnamdo
Country [105] 0 0
Korea, Republic of
State/province [105] 0 0
Gwangju Gwang Yeogsi
Country [106] 0 0
Korea, Republic of
State/province [106] 0 0
Seoul Teugbyeolsi
Country [107] 0 0
Latvia
State/province [107] 0 0
Riga
Country [108] 0 0
Latvia
State/province [108] 0 0
Adazi
Country [109] 0 0
Latvia
State/province [109] 0 0
Daugavpils
Country [110] 0 0
Lithuania
State/province [110] 0 0
Kaunas
Country [111] 0 0
Lithuania
State/province [111] 0 0
Klaipeda
Country [112] 0 0
Lithuania
State/province [112] 0 0
Vilnius
Country [113] 0 0
New Zealand
State/province [113] 0 0
Auckland
Country [114] 0 0
Poland
State/province [114] 0 0
Kujawsko-pomorskie
Country [115] 0 0
Poland
State/province [115] 0 0
Mazowieckie
Country [116] 0 0
Poland
State/province [116] 0 0
Warminsko-mazurskie
Country [117] 0 0
Poland
State/province [117] 0 0
Wielkopolskie
Country [118] 0 0
Portugal
State/province [118] 0 0
Porto
Country [119] 0 0
Portugal
State/province [119] 0 0
Setubal
Country [120] 0 0
Portugal
State/province [120] 0 0
Viana Do Castelo
Country [121] 0 0
Puerto Rico
State/province [121] 0 0
Bayamon
Country [122] 0 0
Puerto Rico
State/province [122] 0 0
San Juan
Country [123] 0 0
Romania
State/province [123] 0 0
Cluj
Country [124] 0 0
Romania
State/province [124] 0 0
Brasov
Country [125] 0 0
Romania
State/province [125] 0 0
Bucuresti
Country [126] 0 0
Serbia
State/province [126] 0 0
Beograd
Country [127] 0 0
Serbia
State/province [127] 0 0
Vojvodina
Country [128] 0 0
Serbia
State/province [128] 0 0
Novi Sad
Country [129] 0 0
Slovakia
State/province [129] 0 0
Kosicky Kraj
Country [130] 0 0
Slovakia
State/province [130] 0 0
Zilinsky Kraj
Country [131] 0 0
Slovakia
State/province [131] 0 0
Košice II
Country [132] 0 0
Slovakia
State/province [132] 0 0
Piestany
Country [133] 0 0
South Africa
State/province [133] 0 0
Gauteng
Country [134] 0 0
South Africa
State/province [134] 0 0
Kwazulu-Natal
Country [135] 0 0
South Africa
State/province [135] 0 0
Western Cape
Country [136] 0 0
Spain
State/province [136] 0 0
A Coruna
Country [137] 0 0
Spain
State/province [137] 0 0
Pontevedra
Country [138] 0 0
Spain
State/province [138] 0 0
Sevilla
Country [139] 0 0
Switzerland
State/province [139] 0 0
Basel-Stadt
Country [140] 0 0
Switzerland
State/province [140] 0 0
Sankt Gallen
Country [141] 0 0
Switzerland
State/province [141] 0 0
Bern
Country [142] 0 0
Taiwan
State/province [142] 0 0
Taipei
Country [143] 0 0
Taiwan
State/province [143] 0 0
Keelung
Country [144] 0 0
Taiwan
State/province [144] 0 0
Taichung
Country [145] 0 0
Turkey
State/province [145] 0 0
Ankara
Country [146] 0 0
Turkey
State/province [146] 0 0
Antalya
Country [147] 0 0
Turkey
State/province [147] 0 0
Meram Konya
Country [148] 0 0
Turkey
State/province [148] 0 0
Trabzon
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Cambridgeshire
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Hampshire
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Northamptonshire
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Northern Ireland
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Luton
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Portsmouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed.

Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo (does not contain treatment drug) . This study comprised of 3 sub studies. In Study 1 and Study 2, study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Eligible participants from Study 1 and Study 2 will enter Study 3 at week 52 to receive specific doses of upadacitinib based on their disease activity and their original treatment assignment in Study 1 or 2. Approximately 500 participants diagnosed with SLE will be enrolled in each of the Study 1 and Study 2 in approximately 320 sites across the world.

Participants will receive oral tablets of upadacitinib or matching placebo once daily for 52 weeks in Study 1 and Study 2. Eligible participants from Study 1 and Study 2 will receive oral tablets of upadacitinib once daily for 52 weeks in Study 3.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Trial website
https://clinicaltrials.gov/study/NCT05843643
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
ABBVIE CALL CENTER
Address 0 0
Country 0 0
Phone 0 0
844-663-3742
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05843643